Why the study?
Does low-dose emicizumab prophylaxis improve bleed control and joint outcomes in a real-world pediatric cohort?
Cohort
Does low-dose emicizumab prophylaxis improve bleed control and joint outcomes in a real-world pediatric cohort?
Low-dose emicizumab may represent a practical and cost-effective strategy for improving access to bleeding prophylaxis in resource-limited pediatric settings.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hanumante et al. (2026) conducted a cohort in Bleeding disorder (Hemophilia). Low-dose emicizumab prophylaxis was evaluated on Bleed control and joint outcomes (HJHS score).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: